Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., June 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 9,500 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of May 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年6月3日，馬薩諸塞州牛頓——Karyopharm Therapeutics Inc.（納斯達克代碼：KPTI）一家商業化階段的藥品公司，是新型癌症療法的先驅者，今天宣佈，公司向三名新員工授予總共9,500個受限制的股票單位（RSUs）。這些RSU獎勵於2024年5月31日（“授予日期”）根據公司2022年誘因股票激勵計劃（經修訂）進行授予，作爲符合納斯達克規則5635（c）（4）的新員工與Karyopharm簽訂就業協議的誘因資料。PRNewswire/-- Karyopharm Therapeutics Inc.（納斯達克：KPTI）是一家商業化階段的藥品公司，致力於開發新型癌症治療方案。今天宣佈，公司向三位新僱員發放了總計9,500股受限制股票單位（RSU）。這些RSU獎勵於2024年5月31日（“授予日期”）根據公司的2022年引誘股票激勵計劃（已修訂），作爲新員工進入Karyopharm就業的誘因，並符合納斯達克上市規則5635（c）（4）。
In addition, the Company granted an award of 200,000 RSUs to Michael Method, MD, MPH, MBA, the Company's Senior Vice President, Clinical Development, with a grant date of May 31, 2024.
此外，公司向Michael Method博士（MD，MPH，MBA），公司的高級副總裁，臨床發展，授予了200,000個限制性股票單位（RSU），授予日期爲2024年5月31日。
Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable RSU agreement).
每個RSU獎勵將在三年內分期歸屬，其中每個RSU獎勵股份的33 1/3％將在授予日之後的三個連續****上獲得。每個RSU獎勵的歸屬取決於員工在適用歸屬日期之前作爲Karyopharm的僱員或其他服務提供商的繼續服務。此外，如果在“控制權變更事件”完成的第一****之前，員工因“良好的理由”被員工解僱或被Karyopharm無“原因”解僱，則每個RSU獎勵將立即完全行權（如適用的RSU協議中所定義）。
About Karyopharm Therapeutics
關於Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics Inc. （納斯達克：KPTI）是一家商業化階段的藥品公司，致力於開發新型腫瘤治療方法，相信癌症患者的強大力量和勇氣。自成立以來，Karyopharm公司一直是口服化合物領域的領導者，這些化合物解決了核蛋白運輸調節的基本機制。Karyopharm的主導化合物和首個口服exportin 1（XPO1）抑制劑XPOVIO（selinexor）已在美國獲得批准，並由該公司用於三種腫瘤治療。它還在不斷增加的海外地區和國家（包括歐洲和英國[NEXPOVIO]和中國）獲得多種適應症的監管批准。Karyopharm的專注產品線針對多種高度未滿足的癌症適應症，包括多發性骨髓瘤，子宮內膜癌，骨髓纖維化和瀰漫性大B細胞淋巴瘤（DLBCL）。有關我們的人員，科學和產品線的更多信息，請訪問www.karyopharm.com，並在領英和X上關注我們@Karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的註冊商標。
SOURCE Karyopharm Therapeutics Inc.
消息來源： Karyopharm Therapeutics Inc.
譯文內容由第三人軟體翻譯。